{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+%28or+active+comparator%29&page=2", "query": { "intervention": "Control (or active comparator)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+%28or+active+comparator%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T12:18:26.179Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07215273", "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Mould Infection" ], "interventions": [ { "name": "EL219", "type": "DRUG" }, { "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-13", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215273" }, { "nct_id": "NCT06430879", "title": "Performance Output With Haptics - Evaluating Athlete Response and Unrealized Potential", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Muscle Strength", "Muscle Weakness" ], "interventions": [ { "name": "VICTORY PATCH", "type": "DEVICE" }, { "name": "Sham Patch without VTT", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "SuperPatch Limited LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "18 Years to 30 Years" }, "enrollment_count": 100, "start_date": "2024-07-10", "completion_date": "2024-11-01", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06430879" }, { "nct_id": "NCT02814916", "title": "Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Methicillin-Resistant Staphylococcus Aureus", "Bacterial Infections", "Staphylococcal Skin Infections" ], "interventions": [ { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Oxacillin", "type": "DRUG" }, { "name": "Flucloxacillin", "type": "DRUG" }, { "name": "Cefadroxil", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 199, "start_date": "2017-03-30", "completion_date": "2024-01-01", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 15, "location_summary": "Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Palma", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02814916" }, { "nct_id": "NCT04215952", "title": "Semantic Feature Analysis Treatment for Aphasia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aphasia" ], "interventions": [ { "name": "Semantic Feature Analysis Treatment", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Pittsburgh Healthcare System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-02-24", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215952" }, { "nct_id": "NCT03639246", "title": "Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "AVB-S6-500", "type": "DRUG" }, { "name": "Paclitaxel (Pac)", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Aravive, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 53, "start_date": "2018-12-06", "completion_date": "2022-12-30", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Oakland, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639246" }, { "nct_id": "NCT04869943", "title": "Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Enobosarm", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veru Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 52, "start_date": "2021-10-12", "completion_date": "2024-01-09", "has_results": false, "last_update_posted_date": "2024-01-26", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 34, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04869943" }, { "nct_id": "NCT00492973", "title": "Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteoarthritis", "Post-traumatic; Arthrosis" ], "interventions": [ { "name": "methylprednisolone acetate", "type": "DRUG" }, { "name": "active comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Lexington Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 101, "start_date": "2006-03", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492973" }, { "nct_id": "NCT03332303", "title": "Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vulvar and Vaginal Atrophy" ], "interventions": [ { "name": "Estrace® Cream", "type": "DRUG" }, { "name": "Estradiol Vaginal Cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prasco LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "30 Years to 75 Years · Female only" }, "enrollment_count": 540, "start_date": "2017-10-26", "completion_date": "2018-03-15", "has_results": true, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 27, "location_summary": "Sacramento, California • San Diego, California • Denver, Colorado + 23 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332303" }, { "nct_id": "NCT03346057", "title": "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Reversal of Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 16 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Rocuronium", "type": "DRUG" }, { "name": "Vecuronium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2017-12-20", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03346057" }, { "nct_id": "NCT07282678", "title": "Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression - Major Depressive Disorder", "Transcranial Alternating Current Stimulation" ], "interventions": [ { "name": "Closed-loop tACS", "type": "DEVICE" }, { "name": "Sham Comparator", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Pulvinar Neuro, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 214, "start_date": "2026-09", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-24T12:18:26.179Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07282678" } ] }